These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25176167)

  • 41. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.
    Mitjans M; Serretti A; Fabbri C; Gastó C; Catalán R; Fañanás L; Arias B
    Psychopharmacology (Berl); 2013 Jun; 227(3):509-19. PubMed ID: 23407780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anxiety impairs depression remission in partial responders during extended treatment in late-life.
    Greenlee A; Karp JF; Dew MA; Houck P; Andreescu C; Reynolds CF
    Depress Anxiety; 2010 May; 27(5):451-6. PubMed ID: 20186975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.
    Cutler JA; Rush AJ; McMahon FJ; Laje G
    J Psychopharmacol; 2012 Mar; 26(3):360-7. PubMed ID: 22282879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder.
    Leuchter AF; Hunter AM; Jain FA; Tartter M; Crump C; Cook IA
    J Psychiatr Res; 2017 Jan; 84():174-183. PubMed ID: 27770740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
    Papakostas GI; Larsen K
    Eur Arch Psychiatry Clin Neurosci; 2011 Apr; 261(3):147-56. PubMed ID: 20859636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Citalopram treatment of social anxiety disorder with comorbid major depression.
    Schneier FR; Blanco C; Campeas R; Lewis-Fernandez R; Lin SH; Marshall R; Schmidt AB; Sanchez-Lacay JA; Simpson HB; Liebowitz MR
    Depress Anxiety; 2003; 17(4):191-6. PubMed ID: 12820174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.
    Bobo WV; Angleró GC; Jenkins G; Hall-Flavin DK; Weinshilboum R; Biernacka JM
    Hum Psychopharmacol; 2016 May; 31(3):185-92. PubMed ID: 26999588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
    Ji Y; Hebbring S; Zhu H; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Zeng Z; Schaid D; Mrazek DA; Kaddurah-Daouk R; Weinshilboum RM
    Clin Pharmacol Ther; 2011 Jan; 89(1):97-104. PubMed ID: 21107318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment.
    Lopez-Vilchez I; Serra-Millas M; Navarro V; Rosa Hernandez M; Villalta J; Diaz-Ricart M; Gasto C; Escolar G; Galan AM
    J Affect Disord; 2014 Apr; 159():39-45. PubMed ID: 24679387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression.
    Fang Y; Qiu Q; Zhang S; Sun L; Li G; Xiao S; Li X
    J Affect Disord; 2018 Feb; 227():745-751. PubMed ID: 29689690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.